Tokyo Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis

Harumi Gomi; Joseph S. Solomkin; David Schlossberg; Kohji Okamoto; Tadahiro Takada; Steven M. Strasberg; Tomohiko Ukai; Itaru Endo; Yukio Iwashita; Taizo Hibi; Henry A. Pitt; Naohisa Matsunaga; Yoriyuki Takamori; Akiko Umezawa; Koji Asai; Kenji Suzuki; Ho Seong Han; Tsann Long Hwang; Yasuhisa Mori; Yoo Seok Yoon; Wayne Shih Wei Huang; Giulio Belli; Christos Dervenis; Masamichi Yokoe; Seiki Kiriyama; Takao Itoi; Palepu Jagannath; O. James Garden; Fumihiko Miura; Eduardo de Santibañes; Satoru Shikata; Yoshinori Noguchi; Keita Wada; Goro Honda; Avinash Nivritti Supe; Masahiro Yoshida; Toshihiko Mayumi; Dirk J. Gouma; Daniel J. Deziel; Kui Hin Liau; Miin Fu Chen; Keng Hao Liu; Cheng Hsi Su; Angus C.W. Chan; Dong Sup Yoon; In Seok Choi; Eduard Jonas; Xiao Ping Chen; Sheung Tat Fan; Chen Guo Ker; Mariano Eduardo Giménez; Seigo Kitano; Masafumi Inomata; Shuntaro Mukai; Ryota Higuchi; Koichi Hirata; Kazuo Inui; Yoshinobu Sumiyama; Masakazu Yamamoto

doi:10.1002/jhbp.518

Tokyo Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis

Harumi Gomi
, Joseph S. Solomkin
, David Schlossberg
, Kohji Okamoto
, Tadahiro Takada^*
, Steven M. Strasberg
, Tomohiko Ukai
, Itaru Endo
, Yukio Iwashita
, Taizo Hibi
, Henry A. Pitt
, Naohisa Matsunaga
, Yoriyuki Takamori
, Akiko Umezawa
, Koji Asai
, Kenji Suzuki
, Ho Seong Han
, Tsann Long Hwang
, Yasuhisa Mori
, Yoo Seok Yoon

Wayne Shih Wei Huang, Giulio Belli, Christos Dervenis, Masamichi Yokoe, Seiki Kiriyama, Takao Itoi, Palepu Jagannath, O. James Garden, Fumihiko Miura, Eduardo de Santibañes, Satoru Shikata, Yoshinori Noguchi, Keita Wada, Goro Honda, Avinash Nivritti Supe, Masahiro Yoshida, Toshihiko Mayumi, Dirk J. Gouma, Daniel J. Deziel, Kui Hin Liau, Miin Fu Chen, Keng Hao Liu, Cheng Hsi Su, Angus C.W. Chan, Dong Sup Yoon, In Seok Choi, Eduard Jonas, Xiao Ping Chen, Sheung Tat Fan, Chen Guo Ker, Mariano Eduardo Giménez, Seigo Kitano, Masafumi Inomata, Shuntaro Mukai, Ryota Higuchi, Koichi Hirata, Kazuo Inui, Yoshinobu Sumiyama, Masakazu Yamamoto

^*Corresponding author for this work

Mito Kyodo General Hospital
University of Cincinnati
Temple University
Kitakyushu City Yahata Hospital
Teikyo University
Washington University St. Louis
Mie Prefectural Ichishi Hospital
Yokohama City University
Oita University
Keio University
Minimally Invasive Surgery Center
Toho University
Fujinomiya City General Hospital
Seoul National University
Chang Gung Memorial Hospital
Kyushu University
Show-Chwan Memorial Hospital Taiwan
Loreto Nuovo Hospital
Agia Olga Hospital
Japanese Red Cross Nagoya Daini Hospital
Ogaki Municipal Hospital
Tokyo Medical University
Lilavati Hospital and Research Centre
University of Edinburgh
Universidad de Buenos Aires
Tokyo Metropolitan Komagome Hospital
Seth GS Medical College and KEM Hospital
International University of Health and Welfare
Japan Council for Quality Health Care
University of Occupational and Environmental Health, Japan
Academic Medical Center
Rush-Presbyt.-St. Luke's Med. Center
National University of Singapore
Cheng Hsin General Hospital
Hong Kong Sanatorium & Hospital
Yonsei University
Konyang University
University of Cape Town
Huazhong University of Science and Technology
Yuan's General Hospital
Tokyo Women's Medical University
Hokkaido Railway Company
Fujita Health University

Research output: Contribution to journal › Journal Article › peer-review

371 Scopus citations

Abstract

Antimicrobial therapy is a mainstay of the management for patients with acute cholangitis and/or cholecystitis. The Tokyo Guidelines 2018 (TG18) provides recommendations for the appropriate use of antimicrobials for community-acquired and healthcare-associated infections. The listed agents are for empirical therapy provided before the infecting isolates are identified. Antimicrobial agents are listed by class-definitions and TG18 severity grade I, II, and III subcategorized by clinical settings. In the era of emerging and increasing antimicrobial resistance, monitoring and updating local antibiograms is underscored. Prudent antimicrobial usage and early de-escalation or termination of antimicrobial therapy are now important parts of decision-making. What is new in TG18 is that the duration of antimicrobial therapy for both acute cholangitis and cholecystitis is systematically reviewed. Prophylactic antimicrobial usage for elective endoscopic retrograde cholangiopancreatography is no longer recommended and the section was deleted in TG18. Free full articles and mobile app of TG18 are available at: http://www.jshbps.jp/modules/en/index.php?content_id=47. Related clinical questions and references are also included.

Original language	English
Pages (from-to)	3-16
Number of pages	14
Journal	Journal of Hepato-Biliary-Pancreatic Sciences
Volume	25
Issue number	1
DOIs	https://doi.org/10.1002/jhbp.518
State	Published - 01 2018
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2018 Japanese Society of Hepato-Biliary-Pancreatic Surgery

Keywords

Acute cholangitis
Acute cholecystitis
Antimicrobial therapy
Biliary tract infection
Treatment guidelines

Access to Document

10.1002/jhbp.518

Cite this

Gomi, H., Solomkin, J. S., Schlossberg, D., Okamoto, K., Takada, T., Strasberg, S. M., Ukai, T., Endo, I., Iwashita, Y., Hibi, T., Pitt, H. A., Matsunaga, N., Takamori, Y., Umezawa, A., Asai, K., Suzuki, K., Han, H. S., Hwang, T. L., Mori, Y., ... Yamamoto, M. (2018). Tokyo Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis. Journal of Hepato-Biliary-Pancreatic Sciences, 25(1), 3-16. https://doi.org/10.1002/jhbp.518

@article{741f6554bda94a9d956aefb6b7d197fa,

title = "Tokyo Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis",

abstract = "Antimicrobial therapy is a mainstay of the management for patients with acute cholangitis and/or cholecystitis. The Tokyo Guidelines 2018 (TG18) provides recommendations for the appropriate use of antimicrobials for community-acquired and healthcare-associated infections. The listed agents are for empirical therapy provided before the infecting isolates are identified. Antimicrobial agents are listed by class-definitions and TG18 severity grade I, II, and III subcategorized by clinical settings. In the era of emerging and increasing antimicrobial resistance, monitoring and updating local antibiograms is underscored. Prudent antimicrobial usage and early de-escalation or termination of antimicrobial therapy are now important parts of decision-making. What is new in TG18 is that the duration of antimicrobial therapy for both acute cholangitis and cholecystitis is systematically reviewed. Prophylactic antimicrobial usage for elective endoscopic retrograde cholangiopancreatography is no longer recommended and the section was deleted in TG18. Free full articles and mobile app of TG18 are available at: http://www.jshbps.jp/modules/en/index.php?content\_id=47. Related clinical questions and references are also included.",

keywords = "Acute cholangitis, Acute cholecystitis, Antimicrobial therapy, Biliary tract infection, Treatment guidelines",

author = "Harumi Gomi and Solomkin, \{Joseph S.\} and David Schlossberg and Kohji Okamoto and Tadahiro Takada and Strasberg, \{Steven M.\} and Tomohiko Ukai and Itaru Endo and Yukio Iwashita and Taizo Hibi and Pitt, \{Henry A.\} and Naohisa Matsunaga and Yoriyuki Takamori and Akiko Umezawa and Koji Asai and Kenji Suzuki and Han, \{Ho Seong\} and Hwang, \{Tsann Long\} and Yasuhisa Mori and Yoon, \{Yoo Seok\} and Huang, \{Wayne Shih Wei\} and Giulio Belli and Christos Dervenis and Masamichi Yokoe and Seiki Kiriyama and Takao Itoi and Palepu Jagannath and Garden, \{O. James\} and Fumihiko Miura and \{de Santiba{\~n}es\}, Eduardo and Satoru Shikata and Yoshinori Noguchi and Keita Wada and Goro Honda and Supe, \{Avinash Nivritti\} and Masahiro Yoshida and Toshihiko Mayumi and Gouma, \{Dirk J.\} and Deziel, \{Daniel J.\} and Liau, \{Kui Hin\} and Chen, \{Miin Fu\} and Liu, \{Keng Hao\} and Su, \{Cheng Hsi\} and Chan, \{Angus C.W.\} and Yoon, \{Dong Sup\} and Choi, \{In Seok\} and Eduard Jonas and Chen, \{Xiao Ping\} and Fan, \{Sheung Tat\} and Ker, \{Chen Guo\} and Gim{\'e}nez, \{Mariano Eduardo\} and Seigo Kitano and Masafumi Inomata and Shuntaro Mukai and Ryota Higuchi and Koichi Hirata and Kazuo Inui and Yoshinobu Sumiyama and Masakazu Yamamoto",

note = "Publisher Copyright: {\textcopyright} 2018 Japanese Society of Hepato-Biliary-Pancreatic Surgery",

year = "2018",

month = jan,

doi = "10.1002/jhbp.518",

language = "英语",

volume = "25",

pages = "3--16",

journal = "Journal of Hepato-Biliary-Pancreatic Sciences",

issn = "1868-6974",

publisher = "Wiley-Blackwell",

number = "1",

}

Gomi, H, Solomkin, JS, Schlossberg, D, Okamoto, K, Takada, T, Strasberg, SM, Ukai, T, Endo, I, Iwashita, Y, Hibi, T, Pitt, HA, Matsunaga, N, Takamori, Y, Umezawa, A, Asai, K, Suzuki, K, Han, HS, Hwang, TL, Mori, Y, Yoon, YS, Huang, WSW, Belli, G, Dervenis, C, Yokoe, M, Kiriyama, S, Itoi, T, Jagannath, P, Garden, OJ, Miura, F, de Santibañes, E, Shikata, S, Noguchi, Y, Wada, K, Honda, G, Supe, AN, Yoshida, M, Mayumi, T, Gouma, DJ, Deziel, DJ, Liau, KH, Chen, MF, Liu, KH, Su, CH, Chan, ACW, Yoon, DS, Choi, IS, Jonas, E, Chen, XP, Fan, ST, Ker, CG, Giménez, ME, Kitano, S, Inomata, M, Mukai, S, Higuchi, R, Hirata, K, Inui, K, Sumiyama, Y & Yamamoto, M 2018, 'Tokyo Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis', Journal of Hepato-Biliary-Pancreatic Sciences, vol. 25, no. 1, pp. 3-16. https://doi.org/10.1002/jhbp.518

TY - JOUR

T1 - Tokyo Guidelines 2018

T2 - antimicrobial therapy for acute cholangitis and cholecystitis

AU - Gomi, Harumi

AU - Solomkin, Joseph S.

AU - Schlossberg, David

AU - Okamoto, Kohji

AU - Takada, Tadahiro

AU - Strasberg, Steven M.

AU - Ukai, Tomohiko

AU - Endo, Itaru

AU - Iwashita, Yukio

AU - Hibi, Taizo

AU - Pitt, Henry A.

AU - Matsunaga, Naohisa

AU - Takamori, Yoriyuki

AU - Umezawa, Akiko

AU - Asai, Koji

AU - Suzuki, Kenji

AU - Han, Ho Seong

AU - Hwang, Tsann Long

AU - Mori, Yasuhisa

AU - Yoon, Yoo Seok

AU - Huang, Wayne Shih Wei

AU - Belli, Giulio

AU - Dervenis, Christos

AU - Yokoe, Masamichi

AU - Kiriyama, Seiki

AU - Itoi, Takao

AU - Jagannath, Palepu

AU - Garden, O. James

AU - Miura, Fumihiko

AU - de Santibañes, Eduardo

AU - Shikata, Satoru

AU - Noguchi, Yoshinori

AU - Wada, Keita

AU - Honda, Goro

AU - Supe, Avinash Nivritti

AU - Yoshida, Masahiro

AU - Mayumi, Toshihiko

AU - Gouma, Dirk J.

AU - Deziel, Daniel J.

AU - Liau, Kui Hin

AU - Chen, Miin Fu

AU - Liu, Keng Hao

AU - Su, Cheng Hsi

AU - Chan, Angus C.W.

AU - Yoon, Dong Sup

AU - Choi, In Seok

AU - Jonas, Eduard

AU - Chen, Xiao Ping

AU - Fan, Sheung Tat

AU - Ker, Chen Guo

AU - Giménez, Mariano Eduardo

AU - Kitano, Seigo

AU - Inomata, Masafumi

AU - Mukai, Shuntaro

AU - Higuchi, Ryota

AU - Hirata, Koichi

AU - Inui, Kazuo

AU - Sumiyama, Yoshinobu

AU - Yamamoto, Masakazu

PY - 2018/1

Y1 - 2018/1

N2 - Antimicrobial therapy is a mainstay of the management for patients with acute cholangitis and/or cholecystitis. The Tokyo Guidelines 2018 (TG18) provides recommendations for the appropriate use of antimicrobials for community-acquired and healthcare-associated infections. The listed agents are for empirical therapy provided before the infecting isolates are identified. Antimicrobial agents are listed by class-definitions and TG18 severity grade I, II, and III subcategorized by clinical settings. In the era of emerging and increasing antimicrobial resistance, monitoring and updating local antibiograms is underscored. Prudent antimicrobial usage and early de-escalation or termination of antimicrobial therapy are now important parts of decision-making. What is new in TG18 is that the duration of antimicrobial therapy for both acute cholangitis and cholecystitis is systematically reviewed. Prophylactic antimicrobial usage for elective endoscopic retrograde cholangiopancreatography is no longer recommended and the section was deleted in TG18. Free full articles and mobile app of TG18 are available at: http://www.jshbps.jp/modules/en/index.php?content_id=47. Related clinical questions and references are also included.

AB - Antimicrobial therapy is a mainstay of the management for patients with acute cholangitis and/or cholecystitis. The Tokyo Guidelines 2018 (TG18) provides recommendations for the appropriate use of antimicrobials for community-acquired and healthcare-associated infections. The listed agents are for empirical therapy provided before the infecting isolates are identified. Antimicrobial agents are listed by class-definitions and TG18 severity grade I, II, and III subcategorized by clinical settings. In the era of emerging and increasing antimicrobial resistance, monitoring and updating local antibiograms is underscored. Prudent antimicrobial usage and early de-escalation or termination of antimicrobial therapy are now important parts of decision-making. What is new in TG18 is that the duration of antimicrobial therapy for both acute cholangitis and cholecystitis is systematically reviewed. Prophylactic antimicrobial usage for elective endoscopic retrograde cholangiopancreatography is no longer recommended and the section was deleted in TG18. Free full articles and mobile app of TG18 are available at: http://www.jshbps.jp/modules/en/index.php?content_id=47. Related clinical questions and references are also included.

KW - Acute cholangitis

KW - Acute cholecystitis

KW - Antimicrobial therapy

KW - Biliary tract infection

KW - Treatment guidelines

UR - https://www.scopus.com/pages/publications/85040726775

U2 - 10.1002/jhbp.518

DO - 10.1002/jhbp.518

M3 - 文章

C2 - 29090866

AN - SCOPUS:85040726775

SN - 1868-6974

VL - 25

SP - 3

EP - 16

JO - Journal of Hepato-Biliary-Pancreatic Sciences

JF - Journal of Hepato-Biliary-Pancreatic Sciences

IS - 1

ER -

Tokyo Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this